Efficacy and tolerability of dolutegravir and two nucleos(t) ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients

被引：43

作者：

Borghetti, Alberto ^{[1
]}

Baldin, Gianmaria ^{[1
]}

Capetti, Amedeo ^{[2
]}

Sterrantino, Gaetana ^{[3
]}

Rusconi, Stefano ^{[4
]}

Latini, Alessandra ^{[5
]}

Giacometti, Andrea ^{[6
]}

Madeddu, Giordano ^{[7
]}

Picarelli, Chiara ^{[1
]}

De Marco, Ramona ^{[1
]}

Cossu, Maria V. ^{[2
]}

Lagi, Filippo ^{[3
]}

Cauda, Roberto ^{[1
]}

De Luca, Andrea ^{[8
]}

Di Giambenedetto, Simona ^{[1
]}

机构：

[1] Univ Cattolica Sacro Cuore, Inst Clin Infect Dis, Policlin Gemelli, Rome, Italy

[2] Luigi Sacco Univ Hosp, Div Infect Dis, Dept Infect Dis, Milan, Italy

[3] Careggi Hosp, Div Trop & Infect Dis, Florence, Italy

[4] Univ Milan, Infect Dis Unit, DIBIC Luigi Sacco, Milan, Italy

[5] IFO S Gallicano Inst IRCCS, Infect Dermatol & Allergol Unit, Rome, Italy

[6] Univ Politecn Marche, Inst Infect Dis & Publ Hlth, Ancona, Italy

[7] Univ Sassari, Dept Clin & Expt Med, Sassari, Italy

[8] Siena Univ Hosp, Univ Div Infect Dis, Siena, Italy

来源：

AIDS | 2017年 / 31卷 / 03期

关键词：

REGIMENS;

D O I：

10.1097/QAD.0000000000001357

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：457 / 459

页数：4

共 9 条

[1] Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study [J].

Cahn, Pedro ;

Pozniak, Anton L. ;

Mingrone, Horacio ;

Shuldyakov, Andrey ;

Brites, Carlos ;

Andrade-Villanueva, Jaime F. ;

Richmond, Gary ;

Beltran Buendia, Carlos ;

Fourie, Jan ;

Ramgopal, Moti ;

Hagins, Debbie ;

Felizarta, Franco ;

Madruga, Jose ;

Reuter, Tania ;

Newman, Tamara ;

Small, Catherine B. ;

Lombaard, John ;

Grinsztejn, Beatriz ;

Dorey, David ;

Underwood, Mark ;

Griffith, Sandy ;

Min, Sherene .

LANCET, 2013, 382 (9893) :700-708

[2] Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice [J].

de Boer, Mark G. J. ;

van den Berk, Guido E. L. ;

van Holten, Natasja ;

Oryszcyn, Josephine E. ;

Dorama, Willemien ;

Moha, Daoud Ait ;

Brinkman, Kees .

AIDS, 2016, 30 (18) :2831-2834

[3]

Gatell JM, 2015, EUR GUID TREATM HIV

[4]

Gulick RM, GUIDELINES USE ANTIR

[5]

Koteff J, 2015, 15 EUR AIDS C EACS 2

[6]

Lake J, 2016, INT AIDS C 18 22 JUL

[7] 48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1-Infected Patients: A Systematic Review and Network Meta-Analysis [J].

Patel, Dipen A. ;

Snedecor, Sonya J. ;

Tang, Wing Yu ;

Sudharshan, Lavanya ;

Lim, Jessica W. ;

Cuffe, Robert ;

Pulgar, Sonia ;

Gilchrist, Kim A. ;

Camejo, Rodrigo Refoios ;

Stephens, Jennifer ;

Nichols, Garrett .

PLOS ONE, 2014, 9 (09)

[8] Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens [J].

Raffi, F. ;

Esser, S. ;

Nunnari, G. ;

Perez-Valero, I. ;

Waters, L. .

HIV MEDICINE, 2016, 17 :3-16

[9] Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial [J].

Walmsley, Sharon ;

Baumgarten, Axel ;

Berenguer, Juan ;

Felizarta, Franco ;

Florence, Eric ;

Marie-Aude Khuong-Josses ;

Kilby, J. Michael ;

Lutz, Thomas ;

Podzamczer, Daniel ;

Portilla, Joaquin ;

Roth, Norman ;

Wong, Deborah ;

Granier, Catherine ;

Wynne, Brian ;

Pappa, Keith .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 70 (05) :515-519

← 1 →